(or Press Releases): Covering trial activations and trial results.
Presented at ASTRO plenary session, Phase III trial results show three to five radiation treatments improved control at the surgical site compared with a single treatment Delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced the risk of cancer returning at the surgical site compared with delivering…
RadiCaL study results show adding bone-targeting radium-223 to cabozantinib does not improve symptomatic skeletal-related events, highlighting the value of current standard treatments to optimize bone health for patients with bone metastases. Results from the Alliance for Clinical Trials in Oncology’s Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney…
New trial evaluates whether post-transplant consolidation therapy with teclistamab can improve survival in patients with primary plasma cell leukemia The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia…
The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new radiation therapy techniques for lung cancer to treatments for breast cancer side effects, these trials aim to improve outcomes, reduce side effects, and deliver more…
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. This marks a…
The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Alliance A082302 aims to enroll 336 participants in this phase III trial specifically focusing on patients with stage I non-small cell lung cancer. Currently, after…
ARACOG TRIAL reveals patients taking hormone therapy darolutamide had less mental decline compared to men taking enzalutamide for advanced prostate cancer A new randomized Alliance Foundation Trials (AFT) clinical study found that men with advanced prostate cancer taking the hormone therapy medication darolutamide had less cognitive decline compared to men taking enzalutamide. According to results…
The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new radiation therapy techniques for lung cancer to treatments for breast cancer side effects, these trials aim to improve outcomes, reduce side effects, and deliver more…
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by…
Pilot study of Participant Engagement Portal (PEP) tool shows value in creating two-way communication between patients and their clinical teams during clinical studies In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for…